Very long acting CRF2 peptide agonist (COR-1389)
A very long acting CRF2 peptide agonist, COR-1389, has been developed allowing suitable subcutaneously administration for the treatment of chronic diseases of high unmet medical needs, such as obesity and pulmonary hypertension group 2. Preclinical proof of concept has been established with CRF2 agonists for these indications. In preclinical models of obesity, COR-1389 lessened body weight by reducing fat mass while preserving muscle mass, and is expected to ameliorate obesity-related comorbidities. CRF2 agonists have been reported to reduce skeletal muscle mass wasting, improve muscle strength and exercise capacity in multiple preclinical models of sarcopenia. In preclinical models of pulmonary hypertension group 2, COR-1389 has been shown to improve cardiopulmonary function and right ventricular hypertrophy.
COR-1389 is currently in phase 1.